With thirty-nine approvals from the FDA, 2012 triggered a wave of optimism in the pharmaceutical industry. But if 2012 was characterized by an increased number of approvals, the sales potential of many of those new products was underwhelming. For 2013, the number of approvals may have gone down, but the quality (in terms of clinical impact and sales potential) has increased dramatically.
Twenty-seven approvals (twenty four of them drugs) in 2013 may be twelve less than the 2012 haul, but it is still above average across the last two decades. And in any case, the number of approvals is a poor surrogate for the productivity of the industry.
With between five and seven products headed for blockbuster status, and Sovaldi™ potentially reaching peak sales in excess of $10billion annually, the output from the global pharmaceutical industry in 2013 shows signs of return to the glory days of the late 1990s. Indeed, arguably, 2013 may be the best year ever in terms of future sales potential for newly-approved products. Predicted global sales of these medicines five years after launch dwarf the equivalent figure for the class of 2012 by as much as 10-fold. With this kind of R&D productivity, things look rosier for the global pharmaceutical industry than they have done for more than a decade.
DrugBaron was intrigued to see a paper published …More
The acquisition of Pearl Therapeutics for up to …More
The pharmaceutical industry achieved 39 approvals in 2012 …More
Until 18th October, bardoxolone methyl (Abbott/Reata) and BG-12 …More
This week, Pfizer and J&J finally discontinued development …More
It is inevitable that clinical trials will fail. …More
As high stakes battles go, the 20-year competition …More
A new study suggests that factor Xa inhibitors, …More
RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to formal preclinical development and clinical up to Phase IIa. In the last five years, we have witnessed dramatic changes in the drug development …